Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Tenaya Therapeutics
- Study ID
- NCT05112237
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Years - 18 Years
- Healthy Volunteers
- Not accepted
Study Details
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Key Dates
- Start date
- Nov 1, 2021
- Status verified
- Nov 2024
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: RetrospectiveAll patients who meet the eligibility criteria will be eligible for retrospective chart review.
- Arm: Prospective100 patients meeting the eligibility criteria will be followed for 5 years, in addition to a retrospective chart review. Assessments will be completed as part of a participant's regular schedule of physician visits, no additional visits will be required. Aside from a simple annual blood draw, assessments are non-invasive, including a Quality of Life questionnaire.
Primary Outcome Measure
To characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement [ Time Frame: 5 years for prospective group, n/a for retrospective group ]
Central Contacts
- Matthew Pollman, MD650-209-8092
- LaTanya Tomlinson
Locations (21)
Find similar trials in Little Rock, AR
By research site
Arkansas Children's Hospital· Little Rock, ARChildren's Hospital Los Angeles· Los Angeles, CAUniversity of California Davis Health· Sacramento, CARady Children's Hospital - San Diego· San Diego, CAUniversity of Colorado Hospital - Anschutz Medical Campus· Aurora, CONemours Alfred I. Dupont Hospital for Children· Wilmington, DE
Related Studies
- Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by AnthracyclinesPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation RegistryEnrolling By Invitation · University of California, Los Angeles · Phoenix, Arizona
- TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast CancerRecruiting · Mayo Clinic · Gainesville, Florida
- Impella Reverse Remodeling in End-Stage Heart FailureRecruiting · Columbia University · New York, New York